Namely, the genes encoding CBP and p300 harbor point mutations or deletions in approximately 20–40% of DLBCL [88, 91, 92], about 70% of follicular lymphomas (FL) [93], and less frequently in T-cell leukemia, acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome [94, 95]. The gene discussed is EP300; the disease is acute lymphoblastic leukemia.